Masataka Katashima
Impact in
- Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism
- Gastroenterology top 10%
- Gastroesophageal reflux and treatments
Papers in
-
- Pharmacogenetics and Drug Metabolism 5
- Antibiotics Pharmacokinetics and Efficacy 3
- Urology 4
- Urinary Bladder and Prostate Research 4
- Co-authors
- Tatsuji Iga (10 shared papers)Yasufumi Sawada (8 shared papers)Akio Kawamura (5 shared papers)Taiji Sawamoto (9 shared papers)Kenji Tabata (3 shared papers)Koujirou Yamamoto (7 shared papers)Yoji Tokuma (8 shared papers)Kazuyoshi Yamamoto (2 shared papers)
- Journals
- Drug Metabolism and Pharmacokinetics (4 papers)Clinical Therapeutics (4 papers)Bioanalysis (3 papers)Advances in Therapy (3 papers)Chemical and Pharmaceutical Bulletin (2 papers)
- Partner nations
- JapanUnited StatesNetherlands
In The Last Decade
Masataka Katashima
46 papers receiving 523 citations
Peers
Comparison fields: 5 of 77
- Pharmacology 100
- Gastroenterology 42
- Urology 40
- Infectious Diseases 103
- Pharmacology 65
Countries citing papers authored by Masataka Katashima
This map shows the geographic impact of Masataka Katashima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masataka Katashima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masataka Katashima more than expected).
Fields of papers citing papers by Masataka Katashima
This network shows the impact of papers produced by Masataka Katashima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masataka Katashima. The network helps show where Masataka Katashima may publish in the future.
Co-authors
The 25 scholars most cited alongside Masataka Katashima, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. | 2001 | 68 |
| 2 | 1998 | 53 | |
| 3 | 2006 | 35 | |
| 4 | 2007 | 32 | |
| 5 | 2013 | 25 | |
| 6 | 2006 | 25 | |
| 7 | 2017 | 22 | |
| 8 | 2018 | 20 | |
| 9 | 1996 | 19 | |
| 10 | 2015 | 19 | |
| 11 | 2018 | 19 | |
| 12 | 2021 | 17 | |
| 13 | 2012 | 17 | |
| 14 | 1995 | 15 | |
| 15 | 2019 | 13 | |
| 16 | 2012 | 11 | |
| 17 | 2017 | 11 | |
| 18 | 2006 | 11 | |
| 19 | 2019 | 11 | |
| 20 | 1998 | 10 |
About Masataka Katashima
Masataka Katashima is a scholar working on Pharmacology, Urology, Pharmacology, Infectious Diseases and Nephrology, having authored 46 papers that have together received 556 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (5 papers), Antifungal resistance and susceptibility (5 papers), Urinary Bladder and Prostate Research (4 papers), Drug Transport and Resistance Mechanisms (4 papers), Herpesvirus Infections and Treatments (4 papers), Statistical Methods in Clinical Trials (3 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and Biosimilars and Bioanalytical Methods (3 papers). The work is most often cited by research in Pharmacology (100 citations), Gastroenterology (42 citations), Urology (40 citations), Infectious Diseases (103 citations) and Pharmacology (65 citations). Masataka Katashima has collaborated with scholars based in Japan, United States and Netherlands. Frequent co-authors include Tatsuji Iga, Yasufumi Sawada, Akio Kawamura, Taiji Sawamoto, Kenji Tabata, Koujirou Yamamoto, Yoji Tokuma, Kazuyoshi Yamamoto, Yusuke Tanigawara and Takehisa Hata. Their work appears in journals such as Drug Metabolism and Pharmacokinetics, Clinical Therapeutics, Bioanalysis, Advances in Therapy and Chemical and Pharmaceutical Bulletin.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.